Authors: Krungkrai, Jerapan; Supuran, Claudiu T.

Source: Current Pharmaceutical Design, Volume 14, Number 7, March 2008 , pp. 631-640(10)

Publisher: Bentham Science Publishers

Abstract:

Plasmodium falciparum is the protozoan parasite responsible for the majority of life-threatening cases of human malaria, causing more than one million deaths a year. The global emergence of drug-resistant malarial parasites necessitates identification and characterization of novel drug targets. At present, α-carbonic anhydrase (CA) genes are identified in limited numbers of parasites in both protozoa and helminthes, however, the malarial genes are found in four species of Plasmodium. The CA gene of P. falciparum encodes an α- carbonic anhydrase enzyme possessing catalytic properties distinct of that of the human host CA I and II isozymes. P. falciparum native and recombinant enzymes have been prepared. A library of aromatic sulfonamides, most of which were Schiff's bases derived from sulfanilamide/ homosulfanilamide/4-aminoethyl-benzenesulfonamide and substituted-aromatic aldehydes, or ureido-substituted sulfonamides are very good inhibitors for P. falciparum enzyme with Ki values in the range of 80 nM-0.50 μM. The 4-(3,4-dichlorophenylureidoethyl)- benzenesulfonamide is the most effective antimalarial activity against growth of P. falciparum in vitro with an IC50 of 2 μM. The structure of the groups substituting the aromatic-ureido- or aromatic-azomethine fragment of the molecule and the length of the parent sulfonamide (i.e., from sulfanilamide to 4-aminoethylbenzenesulfonamide) from which the Schiff's base obtained, are the critical parameters for the enzyme inhibitory activities of these aromatic sulfonamide derivatives, both against the malarial as well as human enzymes. This review provides further support that the CA may have essential roles in the parasite metabolism. Thus, the aromatic sulfonamide CA inhibitors may have potential for development of novel antimalarial drugs.

Keywords: Alpha-carbonic anhydrase; carbonic anhydrase inhibitor; aromatic sulfonamides; antimalarial agents; drug design; malaria parasite; protozoa; helminthes

Document Type: Research article

DOI: http://dx.doi.org/10.2174/138161208783877901

Affiliations: 1: Department of Biochemistry,Faculty of Medicine, Chulalongkorn University, 1873 Rama 4 Road,Pathumwan, Bangkok 10330, Thailand.

Publication date: 2008-03-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Krungkrai, Jerapan ;  Supuran, Claudiu T.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers